Cargando…
Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma
OBJECTIVE: To evaluate the safety and efficacy of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in the treatment of initially unresectable hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) and to preliminarily explore the mechanism of rapid growt...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700990/ https://www.ncbi.nlm.nih.gov/pubmed/36434548 http://dx.doi.org/10.1186/s12893-022-01848-w |
_version_ | 1784839440853630976 |
---|---|
author | Chen, Haoqi Wang, Xiaowen Zhu, Wenfeng Li, Yang Yu, Zhenyu Li, Hua Yang, Yang Zhu, Shuguang Chen, Xiaolong Wang, Genshu |
author_facet | Chen, Haoqi Wang, Xiaowen Zhu, Wenfeng Li, Yang Yu, Zhenyu Li, Hua Yang, Yang Zhu, Shuguang Chen, Xiaolong Wang, Genshu |
author_sort | Chen, Haoqi |
collection | PubMed |
description | OBJECTIVE: To evaluate the safety and efficacy of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in the treatment of initially unresectable hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) and to preliminarily explore the mechanism of rapid growth of the future liver remnant (FLR). METHODS: Twenty-four patients with HBV-associated HCC who underwent ALPPS in our hospital from August 2014 to January 2021 were retrospectively studied. Propensity score matching was used to compare oncologic outcomes of patients treated with ALPPS and transarterial chemoembolization (TACE). The expression of YAP and JNK in liver tissue after two stages of ALPPS were detected. RESULTS: The median standard liver volume (SLV) was 1471.4 ml. Before second stage of ALPPS, the median FLR increased by 74.4%, and the median FLR/SLV increased from 26.1 to 41.6%. Twenty-two patients (91.7%) received staged hepatectomy after a median interval of 15 (9–24) d. The total incidence of postoperative complications in ALPPS group was 54.5%, and of Clavien–Dindo ≥ IIIb postoperative complications (requiring surgical, endoscopic or radiological intervention under general anesthesia) was 9.1%. There was no significant difference in total complications between ALPPS group and TACE group, but there were lower rate of above grade III complications in the TACE group than that in the ALPPS group. The incidence of complications was lower in laparoscopic-ALPPS than that in open surgery. In ALPPS group, the 1-year, 2-year and 5-year overall survival rate were respectively 71.4%, 33.3% and 4.8%. Interval time was an independent risk factor associated with overall survival rate. There was no significant difference in overall survival rate between ALPPS group and TACE group. For advanced HCC (BCLC stage B and C), ALPPS group was not superior to TACE group in overall survival rate. The expression of YAP and p-JNK in the residual liver tissue after second stage procedure was higher than that after first stage procedure, and the co-expression of YAP and p-JNK was observed in the residual liver tissue. CONCLUSION: ALPPS is a safe and effective treatment for initially unresectable HBV-associated HCC. Laparoscopic technique might improve the effect of ALPPS. YAP and JNK pathway might take a role in rapid FLR increase in ALPPS procedure. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12893-022-01848-w. |
format | Online Article Text |
id | pubmed-9700990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97009902022-11-27 Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma Chen, Haoqi Wang, Xiaowen Zhu, Wenfeng Li, Yang Yu, Zhenyu Li, Hua Yang, Yang Zhu, Shuguang Chen, Xiaolong Wang, Genshu BMC Surg Research OBJECTIVE: To evaluate the safety and efficacy of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in the treatment of initially unresectable hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) and to preliminarily explore the mechanism of rapid growth of the future liver remnant (FLR). METHODS: Twenty-four patients with HBV-associated HCC who underwent ALPPS in our hospital from August 2014 to January 2021 were retrospectively studied. Propensity score matching was used to compare oncologic outcomes of patients treated with ALPPS and transarterial chemoembolization (TACE). The expression of YAP and JNK in liver tissue after two stages of ALPPS were detected. RESULTS: The median standard liver volume (SLV) was 1471.4 ml. Before second stage of ALPPS, the median FLR increased by 74.4%, and the median FLR/SLV increased from 26.1 to 41.6%. Twenty-two patients (91.7%) received staged hepatectomy after a median interval of 15 (9–24) d. The total incidence of postoperative complications in ALPPS group was 54.5%, and of Clavien–Dindo ≥ IIIb postoperative complications (requiring surgical, endoscopic or radiological intervention under general anesthesia) was 9.1%. There was no significant difference in total complications between ALPPS group and TACE group, but there were lower rate of above grade III complications in the TACE group than that in the ALPPS group. The incidence of complications was lower in laparoscopic-ALPPS than that in open surgery. In ALPPS group, the 1-year, 2-year and 5-year overall survival rate were respectively 71.4%, 33.3% and 4.8%. Interval time was an independent risk factor associated with overall survival rate. There was no significant difference in overall survival rate between ALPPS group and TACE group. For advanced HCC (BCLC stage B and C), ALPPS group was not superior to TACE group in overall survival rate. The expression of YAP and p-JNK in the residual liver tissue after second stage procedure was higher than that after first stage procedure, and the co-expression of YAP and p-JNK was observed in the residual liver tissue. CONCLUSION: ALPPS is a safe and effective treatment for initially unresectable HBV-associated HCC. Laparoscopic technique might improve the effect of ALPPS. YAP and JNK pathway might take a role in rapid FLR increase in ALPPS procedure. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12893-022-01848-w. BioMed Central 2022-11-24 /pmc/articles/PMC9700990/ /pubmed/36434548 http://dx.doi.org/10.1186/s12893-022-01848-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Chen, Haoqi Wang, Xiaowen Zhu, Wenfeng Li, Yang Yu, Zhenyu Li, Hua Yang, Yang Zhu, Shuguang Chen, Xiaolong Wang, Genshu Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma |
title | Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma |
title_full | Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma |
title_fullStr | Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma |
title_full_unstemmed | Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma |
title_short | Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma |
title_sort | application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700990/ https://www.ncbi.nlm.nih.gov/pubmed/36434548 http://dx.doi.org/10.1186/s12893-022-01848-w |
work_keys_str_mv | AT chenhaoqi applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma AT wangxiaowen applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma AT zhuwenfeng applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma AT liyang applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma AT yuzhenyu applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma AT lihua applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma AT yangyang applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma AT zhushuguang applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma AT chenxiaolong applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma AT wanggenshu applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma |